Standardized Team-Based Care for Cardiogenic Shock.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
09 04 2019
Historique:
received: 29 11 2018
revised: 12 12 2018
accepted: 21 12 2018
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 25 2 2020
Statut: ppublish

Résumé

Cardiogenic shock (CS) is a multifactorial, hemodynamically complex syndrome associated with high mortality. Despite advances in reperfusion and mechanical circulatory support, management remains highly variable and outcomes poor. This study investigated whether a standardized team-based approach can improve outcomes in CS and whether a risk score can guide clinical decision making. A total of 204 consecutive patients with CS were identified. CS etiology, patient demographic characteristics, right heart catheterization, mechanical circulatory support use, and survival were determined. Cardiac power output (CPO) and pulmonary arterial pulsatility index (PAPi) were measured at baseline and 24 h after the CS diagnosis. Thresholds at 24 h for lactate (<3.0 mg/dl), CPO (>0.6 W), and PAPi (>1.0) were determined. Using logistic regression analysis, a validated risk stratification score was developed. Compared with 30-day survival of 47% in 2016, 30-day survival in 2017 and 2018 increased to 57.9% and 76.6%, respectively (p < 0.01). Independent predictors of 30-day mortality were age ≥71 years, diabetes mellitus, dialysis, ≥36 h of vasopressor use at time of diagnosis, lactate levels ≥3.0 mg/dl, CPO <0.6 W, and PAPi <1.0 at 24 h after diagnosis and implementation of therapies. Either 1 or 2 points were assigned to each variable, and a 3-category risk score was determined: 0 to 1 (low), 2 to 4 (moderate), and ≥5 (high). This observational study suggests that a standardized team-based approach may improve CS outcomes. A score incorporating demographic, laboratory, and hemodynamic data may be used to quantify risk and guide clinical decision-making for all phenotypes of CS.

Sections du résumé

BACKGROUND
Cardiogenic shock (CS) is a multifactorial, hemodynamically complex syndrome associated with high mortality. Despite advances in reperfusion and mechanical circulatory support, management remains highly variable and outcomes poor.
OBJECTIVES
This study investigated whether a standardized team-based approach can improve outcomes in CS and whether a risk score can guide clinical decision making.
METHODS
A total of 204 consecutive patients with CS were identified. CS etiology, patient demographic characteristics, right heart catheterization, mechanical circulatory support use, and survival were determined. Cardiac power output (CPO) and pulmonary arterial pulsatility index (PAPi) were measured at baseline and 24 h after the CS diagnosis. Thresholds at 24 h for lactate (<3.0 mg/dl), CPO (>0.6 W), and PAPi (>1.0) were determined. Using logistic regression analysis, a validated risk stratification score was developed.
RESULTS
Compared with 30-day survival of 47% in 2016, 30-day survival in 2017 and 2018 increased to 57.9% and 76.6%, respectively (p < 0.01). Independent predictors of 30-day mortality were age ≥71 years, diabetes mellitus, dialysis, ≥36 h of vasopressor use at time of diagnosis, lactate levels ≥3.0 mg/dl, CPO <0.6 W, and PAPi <1.0 at 24 h after diagnosis and implementation of therapies. Either 1 or 2 points were assigned to each variable, and a 3-category risk score was determined: 0 to 1 (low), 2 to 4 (moderate), and ≥5 (high).
CONCLUSIONS
This observational study suggests that a standardized team-based approach may improve CS outcomes. A score incorporating demographic, laboratory, and hemodynamic data may be used to quantify risk and guide clinical decision-making for all phenotypes of CS.

Identifiants

pubmed: 30947919
pii: S0735-1097(19)30495-4
doi: 10.1016/j.jacc.2018.12.084
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1659-1669

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Behnam N Tehrani (BN)

INOVA Heart and Vascular Institute, Falls Church, Virginia. Electronic address: behnam.tehrani@inova.org.

Alexander G Truesdell (AG)

INOVA Heart and Vascular Institute, Falls Church, Virginia; Virginia Heart, Falls Church, Virginia.

Matthew W Sherwood (MW)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Shashank Desai (S)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Henry A Tran (HA)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Kelly C Epps (KC)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Ramesh Singh (R)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Mitchell Psotka (M)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Palak Shah (P)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Lauren B Cooper (LB)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Carolyn Rosner (C)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Anika Raja (A)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Scott D Barnett (SD)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Patricia Saulino (P)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Christopher R deFilippi (CR)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Paul A Gurbel (PA)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Charles E Murphy (CE)

INOVA Heart and Vascular Institute, Falls Church, Virginia.

Christopher M O'Connor (CM)

INOVA Heart and Vascular Institute, Falls Church, Virginia. Electronic address: christopher.oconnor@inova.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH